Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activity

被引：0
|
作者：
Minamiguchi, K. [1 ]
Seki, M. [1 ]
Aoyagi, H. [1 ]
Mori, T. [1 ]
Kajiwara, D. [1 ]
Masuko, N. [1 ]
Fujita, R. [1 ]
Okajima, S. [1 ]
Hayashi, Y. [1 ]
Sasaki, E. [1 ]
Utsugi, T. [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Tsukuba Res Ctr, Ibaraki, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70441-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [21] Modulators of Androgen and Estrogen Receptor Activity
    Clarke, Bart L.
    Khosla, Sundeep
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2010, 20 (04): : 275 - 294
  • [22] Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor
    Singam, Ettayapuram Ramaprasad Azhagiya
    Tachachartvanich, Phum
    La Merrill, Michele A.
    Smith, Martyn T.
    Durkin, Kathleen A.
    JOURNAL OF PHYSICAL CHEMISTRY B, 2019, 123 (36): : 7657 - 7666
  • [23] A novel route for the synthesis of androgen receptor antagonist enzalutamide
    Meng, Xiangguo
    Bi, Siju
    Jin, Shixin
    Wu, Kai
    Wu, Shanchao
    Shao, Lei
    Bonnet, Pierre-Antoine
    Sheng, Chunquan
    CHINESE CHEMICAL LETTERS, 2023, 34 (06)
  • [24] Permitted Daily Exposure of the Androgen Receptor Antagonist Flutamide
    Zacharia, Lefteris C.
    TOXICOLOGICAL SCIENCES, 2017, 159 (02) : 279 - 289
  • [25] A novel route for the synthesis of androgen receptor antagonist enzalutamide
    Xiangguo Meng
    Siju Bi
    Shixin Jin
    Kai Wu
    Shanchao Wu
    Lei Shao
    Pierre-Antoine Bonnet
    Chunquan Sheng
    Chinese Chemical Letters, 2023, 34 (06) : 479 - 483
  • [26] Biological function and mode of action of the androgen receptor
    Wilson, EM
    PURE AND APPLIED CHEMISTRY, 2003, 75 (11-12) : 1685 - 1697
  • [27] Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy
    Saito, Shun.
    Fujimaki, Takahiro
    Panbangred, Watanalai
    Igarashi, Yasuhiro
    Imoto, Masaya
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (08) : 2728 - 2732
  • [28] Androgen receptor pathway activity and the ratio between androgen and estrogen receptor pathway activity in breast cancer subtypes
    van de Stolpe, Anja
    Wesseling-Rozendaal, Yvonne
    de Inda, Marcia Alves
    van Ooijen, Henk
    Verhaegh, Wim
    CANCER RESEARCH, 2020, 80 (04)
  • [29] First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
    De Bono, Johann S.
    Cook, Natalie
    Yu, Evan Y.
    Lara, Primo
    Wang, Judy S.
    Yamasaki, Yoshihiko
    Yamamiya, Ikuo
    Gao, Ping
    Calleja, Elizabeth Martine
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Phosphorylation dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity
    Wang, LG
    Liu, XM
    Kreis, W
    Budman, DR
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 259 (01) : 21 - 28
12345